Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-400 in Select Advanced Solid Tumor Indications
NCT06084481Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 8
01
Overview
Phase 1, open-label trial of telisotuzumab adizutecan in hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC) and 7 more (10 cohorts), sponsored by AbbVie Inc. Primary endpoints: Objective Response Rate up to 36 Months, Number of Participants with Adverse Events up to 36 Months and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
hepatocellular carcinoma (HCC)pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)Esophageal Squamous Cell Carcinoma (ESCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06084481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084481.